Reuters logo
a year ago
BRIEF-Tokai Pharmaceuticals continuing to evaluate unblinded data from its recently discontinued armor3 clinical trial
August 22, 2016 / 8:26 PM / a year ago

BRIEF-Tokai Pharmaceuticals continuing to evaluate unblinded data from its recently discontinued armor3 clinical trial

Aug 22 (Reuters) - Tokai Pharmaceuticals :

* Continuing to evaluate unblinded data from its recently discontinued armor3 clinical trial comparing galeterone to enzalutamide

* To discontinue enrollment in armor2 expansion clinical trial of galeterone in metastatic castration-resistant prostate cancer patients Source text (bit.ly/2bv9yh8) Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below